Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

The impact of radiotherapy on clinical outcomes in parameningeal rhabdomyosarcoma

  • Choi, Yunseon (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lim, Do Hoon (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2016.05.10
  • Accepted : 2016.07.22
  • Published : 2016.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Radiotherapy (RT) is considered a mainstay of treatment in parameningeal rhabdomyosarcoma (PM-RMS). We aim to determine the treatment outcomes and prognostic factors for PM-RMS patients who treated with RT. In addition, we tried to evaluate the adequate dose and timing of RT. Materials and Methods: Twenty-two patients with PM-RMS from 1995 to 2013 were evaluated. Seven patients had intracranial extension (ICE) and 17 patients had skull base bony erosion (SBBE). Five patients showed distant metastases at the time of diagnosis. All patients underwent chemotherapy and RT. The median radiation dose was 50.4 Gy (range, 40.0 to 56.0 Gy). Results: The median follow-up was 28.7 months. Twelve patients (54.5%) experienced failure after treatment; 4 local, 2 regional, and 6 distant failures. The 5-year local control (LC) and overall survival (OS) were 77.7% and 38.5%, respectively. The 5-year OS rate was 50.8% for patients without distant metastases and 0% for patients with metastases (p < 0.001). Radiation dose (<50 Gy vs. ${\geq}50Gy$) did not compromise the LC (p = 0.645). However, LC was affected by ICE (p = 0.031). Delayed administration (>22 weeks) of RT was related to a higher rate of local failure (40.0%). Conclusion: RT resulted in a higher rate of local control in PM-RMS. However, it was not extended to survival outcome. A more effective treatment for PM-RMS is warranted.

Keywords

References

  1. Wharam MD Jr. Rhabdomyosarcoma of parameningeal sites. Semin Radiat Oncol 1997;7:212-6. https://doi.org/10.1016/S1053-4296(97)80005-7
  2. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995;13:610-30. https://doi.org/10.1200/JCO.1995.13.3.610
  3. Mazzoleni S, Bisogno G, Garaventa A, et al. Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma. Cancer 2005;104:183-90. https://doi.org/10.1002/cncr.21138
  4. Yang JC, Wexler LH, Meyers PA, Wolden SL. Parameningeal rhabdomyosarcoma: outcomes and opportunities. Int J Radiat Oncol Biol Phys 2013;85:e61-6. https://doi.org/10.1016/j.ijrobp.2012.03.036
  5. Merks JH, De Salvo GL, Bergeron C, et al. Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North American and European cooperative groups. Ann Oncol 2014;25:231-6. https://doi.org/10.1093/annonc/mdt426
  6. Turner JH, Richmon JD. Head and neck rhabdomyosarcoma: a critical analysis of population-based incidence and survival data. Otolaryngol Head Neck Surg 2011;145:967-73. https://doi.org/10.1177/0194599811417063
  7. Spalding AC, Hawkins DS, Donaldson SS, et al. The effect of radiation timing on patients with high-risk features of parameningeal rhabdomyosarcoma: an analysis of IRS-IV and D9803. Int J Radiat Oncol Biol Phys 2013;87:512-6. https://doi.org/10.1016/j.ijrobp.2013.07.003
  8. Douglas JG, Arndt CA, Hawkins DS. Delayed radiotherapy following dose intensive chemotherapy for parameningeal rhabdomyosarcoma (PM-RMS) of childhood. Eur J Cancer 2007;43:1045-50. https://doi.org/10.1016/j.ejca.2007.01.033
  9. Raney RB, Maurer HM, Anderson JR, et al. The Intergroup Rhabdomyosarcoma Study Group (IRSG): major lessons from the IRS-I through IRS-IV Studies as background for the current IRS-V treatment protocols. Sarcoma 2001;5:9-15. https://doi.org/10.1080/13577140120048890
  10. Michalski JM, Meza J, Breneman JC, et al. Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV. Int J Radiat Oncol Biol Phys 2004;59:1027-38. https://doi.org/10.1016/j.ijrobp.2004.02.064
  11. Puri DR, Wexler LH, Meyers PA, La Quaglia MP, Healey JH, Wolden SL. The challenging role of radiation therapy for very young children with rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2006;65:1177-84. https://doi.org/10.1016/j.ijrobp.2006.02.014
  12. Breneman J, Meza J, Donaldson SS, et al. Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study. Int J Radiat Oncol Biol Phys 2012;83:720-6. https://doi.org/10.1016/j.ijrobp.2011.06.2011
  13. Park JA, Kim EK, Kang HJ, Shin HY, Kim IH, Ahn HS. Initial response to treatment was highly associated with the prognosis of childhood rhabdomyosarcoma: a retrospective analysis of a single center experience in Korea. Cancer Res Treat 2008;40:111-5. https://doi.org/10.4143/crt.2008.40.3.111
  14. Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001;19:3091-102. https://doi.org/10.1200/JCO.2001.19.12.3091
  15. Raney RB, Asmar L, Vassilopoulou-Sellin R, et al. Late complications of therapy in 213 children with localized, nonorbital soft-tissue sarcoma of the head and neck: a descriptive report from the Intergroup Rhabdomyosarcoma Studies (IRS)-II and -III. IRS Group of the Children's Cancer Group and the Pediatric Oncology Group. Med Pediatr Oncol 1999;33:362-71. https://doi.org/10.1002/(SICI)1096-911X(199910)33:4<362::AID-MPO4>3.0.CO;2-I
  16. Childs SK, Kozak KR, Friedmann AM, et al. Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects. Int J Radiat Oncol Biol Phys 2012;82:635-42. https://doi.org/10.1016/j.ijrobp.2010.11.048
  17. Wolden SL, La TH, LaQuaglia MP, Meyers PA, Kraus DH, Wexler LH. Long-term results of three-dimensional conformal radiation therapy for patients with rhabdomyosarcoma. Cancer 2003;97:179-85. https://doi.org/10.1002/cncr.11001
  18. Wolden SL, Wexler LH, Kraus DH, Laquaglia MP, Lis E, Meyers PA. Intensity-modulated radiotherapy for head-and-neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2005;61:1432-8. https://doi.org/10.1016/j.ijrobp.2004.08.005
  19. Hawkins DS, Anderson JR, Paidas CN, et al. Improved outcome for patients with middle ear rhabdomyosarcoma: a children's oncology group study. J Clin Oncol 2001;19:3073-9. https://doi.org/10.1200/JCO.2001.19.12.3073

Cited by

  1. Treatment Outcomes and Prognostic Factors of Adult Sinonasal Sarcomas: A Single-Institution Case Series vol.24, pp.None, 2018, https://doi.org/10.12659/msm.909116